Cure8 research brief
NUDT15 gene variants can strongly increase the risk of neutropenia from thiopurine drugs used in IBD. Knowing a child’s NUDT15 status could help prevent serious low white blood cell counts by guiding drug choice or dosing.
Pediatric patients with IBD and their caregivers, pediatric gastroenterologists and other clinicians who prescribe thiopurines, and researchers studying pharmacogenetics in IBD.
The study focuses on genetic testing (NUDT15) that affects how children process thiopurine drugs; having variants raised neutropenia risk. This is an observational cohort from a single center (National Taiwan University Hospital) with follow-up from 2023–2025.
The abstract summarizes genotype frequencies, association with absolute neutrophil count, and occurrence of severe neutropenia among thiopurine users. It does not report detailed dosing algorithms or long-term outcomes in the abstract.
Clinical context: For families and clinicians, this supports the idea that preemptive NUDT15 genotyping can identify children at higher risk of thiopurine-related neutropenia, potentially informing safer prescribing. Decisions about testing and drug choice still require clinical judgment and local guideline alignment.
This is a single-center pediatric cohort reported as an abstract-style article. The findings are based on observational data and genotype–phenotype associations; the abstract does not provide detailed clinical protocols, nor does it replace guideline recommendations. NUDT15 testing availability and interpretation may vary by region.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
UGI involvement in children with IBD was common and linked to a more severe disease course — lower remission rates and more frequent need for biologic therapy — which could affect monitoring and treatment planning.
Faster remission can reduce symptoms, school disruption, and steroid exposure for children with IBD. If earlier infliximab level checks reliably speed remission, clinicians could adjust dosing sooner to improve outcomes.
Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...
